...
首页> 外文期刊>Oncology reports >Effects of lentivirus-mediated shRNA targeting integrin-linked kinase on oral squamous cell carcinoma in vitro and in vivo
【24h】

Effects of lentivirus-mediated shRNA targeting integrin-linked kinase on oral squamous cell carcinoma in vitro and in vivo

机译:靶向整合素连接激酶的慢病毒介导的shRNA在体内外对口腔鳞状细胞癌的影响

获取原文
获取原文并翻译 | 示例

摘要

Integrin-linked kinase (ILK), a highly conserved intracellular protein of serine/threonine protein kinase activities, which is associated with the integrin and growth factor receptor signaling pathway, is involved in the regulation of cell proliferation, apoptosis, differentiation, migration and epithelial-mesenchymal transition (EMT). Findings of a previous study showed that ILK overexpression was strongly correlated with a more aggressive tumor phenotype, recurrence and poor survival for oral squamous cell carcinoma (OSCC) patients, as well as some EMT markers. In order to investigate the underlying mechanisms involved, a lentivirus-mediated short hairpin RNA (shRNA) was employed to downregulate ILK. The results showed that the knockdown of ILK inhibited cell growth, adhesion and invasion ability in vitro, and OSCC cells deficient of ILK were blocked in the S phase and underwent apoptosis. Additionally, ILK shRNA inhibited EMT by impairing the expression of Snail, Slug and Twist2 and enhacning E-cadherin expression. ILK shRNA suppressed the phosphorylation of downstream signaling targets Akt and GSk-3 beta. In addition, the knockdown of ILK inhibited tumor growth, invasion and metastasis of xenograft tumors in vivo. These results suggested that ILK is a promising therapeutic target for the treatment of OSCC.
机译:整联蛋白相关激酶(ILK),一种高度保守的丝氨酸/苏氨酸蛋白激酶活性的细胞内蛋白,与整联蛋白和生长因子受体信号通路相关,参与细胞增殖,凋亡,分化,迁移和上皮的调节间质转化(EMT)。先前研究的结果表明,ILK过表达与口腔鳞状细胞癌(OSCC)患者的更具攻击性的肿瘤表型,复发和较差的生存率以及某些EMT标记密切相关。为了研究涉及的潜在机制,采用了慢病毒介导的短发夹RNA(shRNA)下调ILK。结果表明,在体外,ILK的敲低抑制了细胞的生长,粘附和侵袭能力,缺乏ILK的OSCC细胞被阻滞在S期并发生凋亡。此外,ILK shRNA通过削弱Snail,Slug和Twist2的表达并增强E-钙粘蛋白的表达来抑制EMT。 ILK shRNA抑制下游信号传导靶标Akt和GSk-3 beta的磷酸化。另外,ILK的敲低在体内抑制肿瘤生长,异种移植肿瘤的侵袭和转移。这些结果表明,ILK是用于治疗OSCC的有希望的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号